Clostridium difficile Infection

por Feuerstadt, Paul
Publicado 2015

The real efficacy of microbiota restoration following standard of care antimicrobial in patients with recurrent Clostridiodes difficile

por Sehgal, Kanika, Feuerstadt, Paul
Publicado 2023

Evolution of clinical guidelines for antimicrobial management of Clostridioides difficile infection

por Chaar, Abdelkader, Feuerstadt, Paul
Publicado 2021

The burden of CDI in the United States: a multifactorial challenge

por Feuerstadt, Paul, Theriault, Nicolette, Tillotson, Glenn
Publicado 2023

Patient Perception of Route of Rectal Administration of Live Biotherapeutic Product for Recurrent Clostridioides difficile Infection

por Feuerstadt, Paul, Oneto, Caterina, Tillotson, Glenn, Van Hise, Nicholas W
Publicado 2023

Clinical burden of recurrent Clostridioides difficile infection in the medicare population: A real-world claims analysis

por Feuerstadt, Paul, Nelson, Winnie W., Teigland, Christie, Dahdal, David N.
Publicado 2022

Effect of fecal microbial transplantation on Clostridioides difficile infection: dysbiosis, metabolites and health related quality of life

por Garey, Kevin W, Feuerstadt, Paul, Dubberke, Erik R, Guo, Amy, Tillotson, Glenn S
Publicado 2023

Perception of quality of life in people experiencing or having experienced a Clostridioides difficile infection: a US population survey

por Lurienne, Lise, Bandinelli, Pierre-Alain, Galvain, Thibaut, Coursel, Charles-Alexis, Oneto, Caterina, Feuerstadt, Paul
Publicado 2020

Retrospective Analysis of the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA(TM)) Administered Under Enforcement Discretion to Patients With Clostridioides difficile I...

por Feuerstadt, Paul, Harvey, Adam, Yoho, David S, Garcia-Diaz, Julia B, Knapple, Whitfield L, Bancke, Lindy
Publicado 2023

Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims analysis

por Nelson, Winnie W, Scott, Takara A, Boules, Mena, Teigland, Christie, Parente, Alexis, Unni, Sudhir, Feuerstadt, Paul
Publicado 2021

Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection

por Feuerstadt, Paul, Aroniadis, Olga C., Svedlund, Felicia L., Garcia, Mariana, Stong, Laura, Boules, Mena, Khanna, Sahil
Publicado 2021

Clinical complications in patients with primary and recurrent Clostridioides difficile infection: A real-world data analysis

por Feuerstadt, Paul, Boules, Mena, Stong, Laura, Dahdal, David N, Sacks, Naomi C, Lang, Kathleen, Nelson, Winnie W
Publicado 2021

Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent Clostridioides difficile Infection in Older Adults With Underlying Comorbidities

por Tillotson, Glenn, Archbald-Pannone, Laurie, Johnson, Stuart, Ng, Samson, Ando, Masakazu, Harvey, Adam, Bancke, Lindy, Feuerstadt, Paul
Publicado 2022

236. Treatment of Recurrent Clostridioides difficile Infection With RBX2660 in Patients ≥ 65 Years Old With Underlying Comorbidities

por Tillotson, Glenn S, Feuerstadt, Paul, Archbald-Pannone, Laurie, Archbald-Pannone, Laurie, Johnson, Stuart, Ng, Samson, Ando, Masakazu, Harvey, Adam
Publicado 2022

Safety of fecal microbiota, live-jslm (REBYOTA(™)) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials

por Lee, Christine, Louie, Thomas, Bancke, Lindy, Guthmueller, Beth, Harvey, Adam, Feuerstadt, Paul, Khanna, Sahil, Orenstein, Robert, Dubberke, Erik R.
Publicado 2023

Mortality, healthcare resource utilization, and cost among Medicare beneficiaries with Clostridioides difficile infection with and without sepsis

por Amin, Alpesh, Nelson, Winnie W., Dreyfus, Jill, Wong, Anny C., Mohammadi, Iman, Teigland, Christie, Dahdal, David N., Feuerstadt, Paul
Publicado 2022

366. Association Between Gut Microbiota and Health-Related Quality of Life in Patients with Recurrent Clostridioides difficile Infection: Results from the PUNCH CD3 Clinical Trial

por Feuerstadt, Paul, Blount, Ken, Guo, Amy, Yang, Min, García-Horton, Viviana, Fillbrunn, Mirko, Tillotson, Glenn S, Gao, Yipeng, Dubberke, Erik R, Garey, Kevin W
Publicado 2023

522. Significant Improvement in Health-Related Quality of Life (HRQL) with RBX2660: Results from a Phase 3 Randomized, Placebo-Controlled Trial in Recurrent Clostridioides Difficil...

por Feuerstadt, Paul, Dubberke, Erik R, Guo, Amy, Harvey, Adam, Yang, Min, García-Horton, Viviana, Fillbrunn, Mirko, Tillotson, Glenn S, Bancke, Lindy, Garey, Kevin W
Publicado 2022

658. Diagnostic Testing Among Patients with Suspected Recurrent Clostridioides difficile Infection (rCDI) in ECOSPOR III a Phase 3 Clinical Trial: Implications for Clinical Practic...

por Sims, Matthew, Khanna, Sahil, Pardi, Darrell, Feuerstadt, Paul, Berenson, Charles, Wu, Henry, Wang, Elaine E, Wang, Elaine E, McGovern, Barbara, von Moltke, Lisa
Publicado 2021

Effect of Fecal Microbiota, Live-Jslm (REBYOTA [RBL]) on Health-Related Quality of Life in Patients With Recurrent Clostridioides difficile Infection: Results From the PUNCH CD3 Cl...

por Garey, Kevin W, Dubberke, Erik R, Guo, Amy, Harvey, Adam, Yang, Min, García-Horton, Viviana, Fillbrunn, Mirko, Wang, Hongjue, Tillotson, Glenn S, Bancke, Lindy L, Feuerstadt, Paul
Publicado 2023